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GLOSSARY 
 
 
 
 
 
DM   : Diabetes Mellitus 
 
T1 DM  : Type I  Diabetes Mellitus 
 
T2 DM  : Type 2  Diabetes Mellitus 
 
GDM   : Gestational Diabetes Mellitus 
 
MAU   : Micro albuminuria 
 
BMI   : Body Mass Index 
 
OP   : out Patients 
 
GRH   : Government Rajaji Hospital 
 
IDDM   : Insulin dependent Diabetes Mellitus 
 
NIDDM  : Non Insulin dependent Diabetes Mellitus 
 
FPG   : Fasting Plasma Glucose 
 
PPG   : Post Prandial Glucose 
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INTRODUCTION 
 
Nephropathy is one of the common  complication of diabetes and 
can lead to end stage renal failure. The number of diabetic subjects 
accepted for renal dialysis treatment is increasing yearly. Nephropathy 
takes several  years to develop after the diagnosis of diabetes but if it 
is diagnosed early the process can be aborted or even reversed by 
strict metabolic Control.   
 
Nephropathy presents first as intermittent microalbuminuria 
(Incipient), progressing to persistent microalbuminuria and then to 
macroalbuminuria. A useful method of  detection of albumin in urine is 
by quantifying microalbuminuria 
 
Diabetic  retinopathy is one of  leading causes  of blindness in 
the world that increases the chance of loosing the sight about 25 times 
higher compared to normal individuals using new surgical and medical 
techniques the incidence can be reduced to 90% .Microalbuminuria  is 
a  reliable marker for diabetic retinopathy. 
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Microalbuminuria has been proposed as a marker of  generalized 
endothelial dysfunction resulting in  atherothrombotic  vascular 
disease.  
  
In addition to predicting nephropathy in both type 1 & type 2 
diabetes microalbuminuria is a strong predictor of risk for cardio 
vascular disease independent of conventional  risk factors  
 
The recommendation to screen for microalbuminuria is based on 
expert opinion that considered the natural history of Diabetic  
retinopathy and nephropathy the evidence from many randomized 
controlled clinical trials of benefit  of treatment of those patients found 
to have microalbuminuria 
 
DEFINITIONS OF  MICROALBUMINURIA  AND   CLINICAL 
ALBUMINURIA 
 
 mg / 24 hours µgm / minute µgm /mg Creatinine 
Normal <30 <20 <30 
Microalbuminuria 30-300 20-200 30-300 
Clinicalalbuminuria 
 
>300 >200 >300 
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The spot urine collection is the simplest and preferred 
methodology Screening for microalbuminuria should begin as soon as 
possible after the diagnosis type 2 diabetes mellitus and in type 1 
diabetes mellitus should begin with puberty once the duration of 
diabetes mellitus  is more than 5 years  
 
In this background we undertook this study of                   
Patients of Newly detected diabetes mellitus to find out the prevalence 
of microalbuminuria and its association  with diabetic retinopathy in 
southern Tamilnadu patients  attending the Government Rajaji 
Hospital, Madurai, Under the guidance of  Department of Medicine,  
Government Rajaji Hospital, Madurai.  
 
It is hoped that this study may help to prevent the dreaded 
complication of untreated patients of diabetes mellitus. This study also  
stresses the importance of early detection of diabetes mellitus and it’s  
Complications.     
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DIABETES MELLITUS 
 
 
Diabetes mellitus is a group of metabolic disorders with one 
common manifestation: hyperglycemia. Chronic hyperglycemia causes 
damage to the eyes, kidneys, nerves, heart and blood vessels. The 
etiology and pathophysiology leading to the hyperglycemia, however, 
are markedly different among patients with diabetes mellitus, dictating 
different prevention strategies, diagnostic screening methods and 
treatments. The adverse impact of hyperglycemia and the rationale for 
aggressive treatment have recently been reviewed. 
 
In June 1997, an international expert committee released a 
report with new recommendations for the classification and diagnosis 
of diabetes mellitus.These new recommendations were the result of 
more than two years of collaboration among experts from the 
American Diabetes Association and the World Health Organization 
(WHO). The use of classification systems and standardized diagnostic 
criteria facilitates a common language among patients, physicians, 
other health care professionals and scientists.  
 
The National Diabetes Data Group also established the oral 
glucose tolerance test (using a glucose load of 75 g) as the preferred 
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diagnostic test for diabetes mellitus.However, this test has poor 
reproducibility, lacks physiologic relevance and is a weaker indicator of 
long-term complications compared with other measures of 
hyperglycemia. Furthermore, many high-risk patients are unwilling to 
undergo this time-consuming test on a repeat basis.  
 
Etiologic Classifications of Diabetes Mellitus   
 
Type 1 diabetes mellitus (formerly called type I, IDDM or 
juvenile diabetes) is characterized by beta cell destruction caused by 
an autoimmune process, usually leading to absolute insulin deficiency. 
The onset is usually acute, developing over a period of a few days to 
weeks. Over 95 percent of persons with type 1 diabetes mellitus 
develop the disease before the age of 25, with an equal incidence in 
both sexes and an increased prevalence in the white population. A 
family history of type 1 diabetes mellitus, gluten enteropathy (celiac 
disease) or other endocrine disease is often found. Most of these 
patients have the "immune-mediated form" of type 1 diabetes mellitus 
with islet cell antibodies and often have other autoimmune disorders 
such as Hashimoto's thyroiditis, Addison's disease, vitiligo or 
pernicious anemia. A few patients, usually those of African or Asian 
origin, have no antibodies but have a similar clinical presentation; 
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consequently, they are included in this classification and their disease 
is called the "idiopathic form" of type 1 diabetes mellitus. 
 
Type 2 diabetes mellitus (formerly called NIDDM, type II or 
adult-onset) is characterized by insulin resistance in peripheral tissue 
and an insulin secretory defect of the beta cell. This is the most 
common form of diabetes mellitus and is highly associated with a 
family history of diabetes, older age, obesity and lack of exercise. It is 
more common in women, especially women with a history of 
gestational diabetes, and in blacks, Hispanics and Native Americans. 
Insulin resistance and hyperinsulinemia eventually lead to impaired 
glucose tolerance. Defective beta cells become exhausted, further 
fueling the cycle of glucose intolerance and hyperglycemia. The 
etiology of type 2 diabetes mellitus is multifactorial and probably 
genetically based, but it also has strong behavioral components.  
 
Other specific types: 
 
Genetic defects of beta-cell function  
Genetic defects in insulin action  
Diseases of the exocrine pancreas  
Pancreatitis  Pancreatectomy  Trauma   
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Cystic fibrosis  Neoplasia 
Hemochromatosis  
Endocrinopathies  
Acromegaly   Hyperthyroidism   Somatostatinoma 
Cushing's syndrome Aldosteronoma  Glucagonoma     
Pheochromocytoma  
Drug- or chemical-induced  
Vacor†    Pentamidine   Nicotinic acid   
Thyroid hormone   Glucocorticoids   Diazoxide    
Beta-adrenergic agonists Thiazides    Phenytoin 
Infections  
Congenital rubella     Cytomegalovirus  
 
Others Uncommon forms of immune- mediated diabetes  
 
Other genetic syndromes sometimes associated with diabetes  
Down syndrome      Klinefelter's syndrome  
Turner's syndrome     Wolfram syndrome  
Friedreich's ataxia     Huntington's chorea  
Lawrence-Moon Beidel syndrome   Prader-Willi syndrome  
Myotonic dystrophy     Porphyria  
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Gestational diabetes mellitus 
 
Gestational diabetes mellitus is an operational classification 
(rather than a pathophysiologic condition) identifying women who 
develop diabetes mellitus during gestation.(Women with diabetes 
mellitus before pregnancy are said to have "pregestational diabetes" 
and are not included in this group.) Women who develop type 1 
diabetes mellitus during pregnancy and women with undiagnosed 
asymptomatic type 2 diabetes mellitus that is discovered during 
pregnancy are classified with gestational diabetes mellitus. However, 
most women classified with gestational diabetes mellitus have normal 
glucose homeostasis during the first half of the pregnancy and develop 
a relative insulin deficiency during the last half of the pregnancy, 
leading to hyperglycemia. The hyperglycemia resolves in most women 
after delivery but places them at increased risk of developing type 2 
diabetes mellitus later in life.  
 
Criteria for the Diagnosis of Diabetes Mellitus and Impaired 
Glucose Homeostasis  
  
 Diabetes mellitus--positive findings from any two of the following 
tests on different days:  
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Symptoms of diabetes mellitus* plus casual† plasma glucose 
concentration >=200 mg per dL (11.1 mmol per L) Or 
FPG >=126 mg per dL (7.0 mmol per L) Or 
2hrPPG >=200 mg per dL (11.1 mmol per L) after a 75-g glucose 
load  
Impaired fasting glucose: FPG from 110 to <126 (6.1 to 7.0 mmol 
per L)  
Impaired glucose tolerance: 2hrPPG from 140 to <200 (7.75 to 
<11.1 mmol per L)  
Normal  
FPG <110 mg per dL (6.1 mmol per L)  
2hrPPG <140 mg per dL (7.75 mmol per L)   
†--Casual is defined as any time of day without regard to time since 
last meal. 
*--Symptoms include polyuria, polydipsia or unexplained weight loss. 
FPG=fasting plasma glucose; 2hrPPG=two-hour postprandial glucose. 
Both impaired fasting glucose and impaired glucose tolerance are 
associated with an increased risk of developing type 2 diabetes 
mellitus. Lifestyle changes, such as weight loss and exercise, are 
warranted in these patients.  
Screening for gestational diabetes mellitus is generally accomplished 
with administration of a 50-g glucose load one hour before 
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determining a plasma glucose level. A positive screen (defined as a 
plasma glucose level of 140 mg per dL [7.75 mmol per L] or higher) 
should prompt a diagnostic test: fasting plasma glucose levels should 
be measured after a 100-g glucose load at baseline and at one, two 
and three hours after the glucose load. Two of the four values must be 
abnormal (105 mg per dL [5.8 mmol per L] or higher; 190 mg per dL 
[10.5 mmol per L] or higher; 165 mg per dL [9.15 mmol per L] or 
higher; and 145 mg per dL [8.05 mmol per L] or higher) for a patient 
to be diagnosed with gestational diabetes mellitus. The WHO criteria 
use a glucose load of 75 g with a test two hours after the glucose load, 
using the same criterion for the diagnosis of gestational diabetes 
mellitus.  
 
Glycated hemoglobin (also known as glycohemoglobin, 
glycosylated hemoglobin or HbA1c) is used to monitor treatment in 
patients with diabetes mellitus; however, it is not recommended for 
routine diagnosis of this condition because of a lack of standardization 
of tests and results.  Measurements of glycated hemoglobin have 
commonly been used to monitor the glycemic control of persons 
already diagnosed with diabetes mellitus.  
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Recommendations for Diabetes Screening of Asymptomatic 
Persons   
Timing of first test and repeat tests 
Test at age 45; repeat every three years:Patients 45 years of age or 
older  
Test before age 45; repeat more frequently than every three years if 
patient has one or more of the following risk factors: 
Obesity: >=120% of desirable body weight or BMI >=27 kg per m2  
First-degree relative with diabetes mellitus  
Member of high risk-ethnic group (black, Hispanic, Native American, 
Asian)  
History of gestational diabetes mellitus or delivering a baby weighing 
more than 4,032 g (9 lb)  
Hypertensive (>=140/90 mm Hg)  
HDL cholesterol level ¾35 mg per dL (0.90 mmol per L) and/or 
triglyceride level >=250 mg per dL (2.83 mmol per L)  
History of IGT or IFG on prior testing   
BMI=body mass index; HDL=high density lipoprotein; IGT=impaired 
glucose tolerance; IFG=impaired fasting glucose. 
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DIABETIC RETINOPATHY 
 
 
Ophthalmic complications of diabetes include corneal  
 
abnormalities, glaucoma, iris neovascularization, cataracts, and  
 
neuropathies. However, the most common and potentially most  
 
blinding of these is diabetic retinopathy. 
 
 
PATHOPHYSIOLOGY:  
 
The exact mechanism by which diabetes causes retinopathy  
 
remains unclear, but several theories have been postulated to explain  
 
the typical course and history of the disease.  
 
Platelets and blood viscosity : 
 
The variety of hematologic abnormalities seen in diabetes, such  
 
as increased erythrocyte aggregation, decreased RBC deformability,  
 
increased platelet aggregation, and adhesion, predispose to sluggish  
 
circulation, endothelial damage, and focal capillary occlusion. This  
 
leads to retinal ischemia, which in turn contributes to the development  
 
of diabetic retinopathy.  
 
Aldose reductase and vasoproliferative factors : 
 
Fundamentally, DM causes abnormal glucose metabolism as a result of  
 
decreased levels or activity of insulin. Increased levels of blood glucose  
 
are thought to have a structural and physiologic effect on retinal  
 
capillaries causing them to be both functionally and anatomically.  
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incompetent A persistent increase in blood glucose levels shunts  
 
excess glucose into the aldose reductase pathway in certain tissues,  
 
which converts sugars into alcohol (eg, glucose into sorbitol, galactose  
 
to dulcitol). Intramural pericytes of retinal capillaries seem to be,  
 
affected by this increased level of sorbitol eventually leading to the  
 
loss of its primary function (ie, autoregulation of retinal capillaries).  
 
Loss of function of pericytes results in weakness and eventual saccular  
 
outpouching of capillary walls. These microaneurysms are the earliest.  
 
detectable signs of DM retinopathy Ruptured microaneurysms (MA)  
 
result in retinal hemorrhages either superficially (flame-shaped  
 
hemorrhages) or in deeper layers of the retina (blot and dot  
 
hemorrhages). Increased permeability of these vessels results in  
 
leakage of fluid and proteinaceous material, which clinically appears as  
 
retinal thickening and exudates. If the swelling and exudation would  
 
happen to involve the macula, a diminution in central vision may be  
 
experienced. Macular edema is the most common cause of vision loss  
 
in patients with nonproliferative diabetic retinopathy (NPDR). However,  
 
it is not exclusively seen only in patients with NPDR, but it also may  
 
complicate cases of proliferative diabetic retinopathy (PDR).  
 
As the disease progresses, eventual closure of retinal capillaries  
 
occurs, leading to hypoxia. Infarction of the nerve fiber layer leads to  
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the formation of cotton-wool spots (CWS) with associated stasis in 
axoplasmic flow. More extensive retinal hypoxia triggers compensatory 
mechanisms within the eye to provide enough oxygen to tissues. 
Venous caliber abnormalities, such as venous beading, loops, and 
dilation, signify increasing hypoxia and almost always are seen 
bordering the areas of capillary nonperfusion. Intraretinal 
microvascular abnormalities (IRMA) represent either new vessel 
growth or remodeling of preexisting vessels through endothelial cell 
proliferation within the retinal tissues to act as shunts through areas of 
nonperfusion. Further increases in retinal ischemia trigger the 
production of vasoproliferative factors that stimulate new vessel 
formation. The extracellular matrix is broken down first by proteases, 
and new vessels arising mainly from the retinal venules penetrate the 
internal limiting membrane and form capillary networks between the 
inner surface of the retina and the posterior hyaloid face. 
Neovascularization most commonly is observed at the borders of 
perfused and nonperfused retina and most commonly occur along the 
vascular arcades and at the optic nerve head. The new vessels break 
through and grow along the surface of the retina and into the scaffold 
of the posterior hyaloid face. By themselves, these vessels rarely 
cause visual compromise. However, they are fragile and highly 
permeable.  
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These delicate vessels are disrupted easily by vitreous traction, which 
leads to hemorrhage into the vitreous cavity or the preretinal space.  
 
These new blood vessels initially are associated with a small amount of  
fibroglial tissue formation. However, as the density of the neovascular 
frond increases, so does the degree of fibrous tissue formation. In 
later stages, the vessels may regress leaving only networks of 
avascular fibrous tissue adherent to both the retina and the posterior 
hyaloid face. As the vitreous contracts, it may exert tractional forces 
on the retina via these fibroglial connections. Traction may cause 
retinal edema, retinal heterotropia, and both tractional retinal 
detachments and retinal tear formation with subsequent detachment. 
 
History: In the initial stages, patients are generally asymptomatic; 
however, in more advanced stages of the disease, patients may 
experience increasing visual acuity loss. 
 
Physical:  
Microaneurysms 
Earliest clinical sign of diabetic retinopathy Secondary to capillary wall  
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outpouching due to pericyte loss appear as small red dots in the 
superficial retinal layers Fibrin and RBC accumulation in the 
microaneurysm lumen Rupture produces blot/flame hemorrhages May 
appear yellowish in time as endothelial cells proliferate and produce 
basement membrane 
Dot and blot hemorrhages: 
Occur as microaneurysms rupture in the deeper layers of the retina 
such as the inner nuclear and outer plexiform layers Appear similar to  
microaneurysms if they are small; fluorescein angiography may be 
needed to distinguish between the two 
Flame-shaped hemorrhages - Splinter hemorrhages that occur in 
the more superficial nerve fiber layer 
Retinal edema and hard exudates - Caused by the breakdown of 
the blood-retina barrier allowing leakage of serum proteins, lipids, and 
protein from the vessels 
Cotton-wool spots 
Nerve fiber layer infarction from occlusion of precapillary arterioles 
Fluorescein angiography - No capillary perfusion Frequently bordered 
by microaneurysms and vascular hyperpermeability Venous loops, 
venous beading Frequently adjacent to areas of nonperfusion Reflects 
increasing retinal ischemia Most significant predictor of progression to 
PDR 
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Intraretinal microvascular abnormalities 
Remodeled capillary beds without proliferative changes Collateral 
vessels that do not leak on fluorescein angiography Usually can be 
found on the borders of the nonperfused retina 
Macular edema 
This condition is the leading cause of visual impairment in patients 
with diabetes. It has been reported that 75,000 new cases of macular 
edema are diagnosed annually. Possibly due to functional damage and 
necrosis of retinal capillaries Clinically significant macular edema 
(CSME) is defined as any of the following: Retinal thickening located 
500 mm or less from the center of the foveal avascular zone (FAZ) 
Hard exudates with retinal thickening 500 mm or less from the center 
of the FAZ Retinal thickening 1 disc area or larger in size located within 
1 disc diameter of the FAZ  
Mild nonproliferative diabetic retinopathy - Presence of at least 1  
Microaneurysm 
Moderate nonproliferative diabetic retinopathy  
Presence of hemorrhages, microaneurysms, hard exudates  
Soft exudates, venous beading, and IRMA less than that of severe 
NPDRSevere nonproliferative diabetic retinopathy (4-2-1) 
Hemorrhages and microaneurysms in 4 quadrants Venous beading in 
at least 2 quadrants IRMA in at least 1 quadrant Mild NPDR reflects 
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structural changes in the retina caused by the physiological and 
anatomical effects of diabetes. On the other hand, the more advanced 
stages of NPDR reflect the increasing retinal ischemia setting up the 
stage for proliferative changes. 
Causes: Risk factors 
Duration of the diabetes 
In patients with type I diabetes, no clinically significant retinopathy 
can be seen in the first 5 years after the initial diagnosis of diabetes is 
made. After 10-15 years, 25-50% of patients show some signs of 
retinopathy. This prevalence increases to 75-95% after 15 years and 
approaches 100% after 30 years of diabetes. In patients with type II 
diabetes, incidence of diabetic retinopathy increases along with the 
duration of the disease. Of patients, 23% after 11-13 years, 41% after 
14-16 years, and 60% after 16 years have NPDR. 
Glucose control 
The Diabetic Complications Control Trial (DCCT) has 
demonstrated that intensive glucose control reduced the incidence and 
the progression of diabetic retinopathy in patients with insulin-
dependent diabetes mellitus (IDDM).Although no similar trials for non–
insulin–dependent diabetes mellitus (NIDDM) patients have been 
completed, it has been suggested by  
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American Diabetes Association (ADA) that glycosylated 
hemoglobin levels less than 7% (reflecting long-term glucose levels) 
should be the goal in all patients to prevent or slow down the onset of 
diabetes-related complications. 
Renal disease as evidenced by proteinuria, and elevated 
BUN/creatinine levels is an excellent predictor of the presence of 
retinopathy. This probably is due to the fact that both conditions are 
caused by DM-related microangiopathies such that the presence and 
severity of one reflects that of the other. Evidence suggests that 
aggressive treatment of the nephropathy may have a beneficial effect 
on the progression of diabetic retinopathy and neovascular glaucoma. 
Systemic hypertension, in the setting of diabetic nephropathy, 
correlates well with the presence of retinopathy. Independently, 
hypertension also may complicate diabetes in that it may result in 
hypertensive retinal vascular changes superimposed on the preexisting 
diabetic retinopathy further compromising retinal blood flow. 
Elevated serum lipids: It has been suggested that the proper 
management of hyperlipidemia may result in less retinal vessel 
leakage and hard exudate formation. The reason behind this is 
unclear. Pregnant women without any diabetic retinopathy run a 10% 
risk of developing NPDR during their pregnancy. Of those with 
preexisting NPDR, 4% progress to the proliferative type. 
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MICROALBUMINURIA 
 
Diagnosis/Screening 
Diabetes is the leading cause of end-stage renal disease in the Western and 
India . Early detection of diabetic nephropathy relies upon tests for urinary 
excretion of albumin. Conventional qualitative tests for albuminuria do not 
detect the small increases of urinary albumin excretion seen in early stages 
of nephropathy.For this purpose, tests for “microalbuminuria” are used.  
 
Definitions of Microalbuminuria and Clinical Albuminuria* 
The ADA recommends periodic qualitative (“dipstick”) testing for urine 
albumin in adults with diabetes .Positivetests represent “clinical albuminuria” 
or “overt nephropathy” in the ADA recommendations, corresponding to 
protein excretion > 300 mg/24 hours (> 200 µg/min or > 300 µg/mg 
creatinine) In these patients, quantitative measurement of urine protein 
excretion is used in the assessment of the severity of proteinuria and its 
progression, inplanning treatment, and in determining the impact of therapy.  
 
Recommendation: Annual microalbumin testing of patients without clinical 
proteinuria should begin inpubertal or postpubertal individuals five years 
after diagnosis of type 1 diabetes and at the time of diagnosis 
of type 2 diabetes. The role of testing is unclear in patients under treatment 
with angiotensin-convertingenzyme inhibitors and in those with short life 
expectancy. 
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Early detection of microalbuminuria allows early intervention with a goal of 
delaying the onset of overt diabetic nephropathy. 
Microalbuminuria rarely occurs with short duration of type 1 diabetes or 
before puberty. Thus testing is less urgent in these situations. Although the 
difficulty in precisely dating the onset of type 2 diabetes warrants initiation of 
annualtesting early after diagnosis of diabetes, older patients (age > 75 
years or life expectancy < 20 years) may never be atrisk for clinically 
significant nephropathy in view of a projected life-span that is too brief for 
renal dysfunction todevelop. In such patients, the role of treating 
microalbuminuria is far from clear, and the need to screen for it is, thus, 
uncertain at best. The urinary albumin excretion rate reportedly has no 
marked diurnal variation in diabetes, but it does in essential hypertension . 
 
Technique: Semiquantitative or qualitative screening tests for 
microalbuminuria should be positive in >95% of patients with 
microalbuminuria to be useful for screening. Positive results must be 
confirmed by analysis in an accredited laboratory.Qualitative (or 
semiquantitative) tests for microalbuminuria have been proposed for use as 
screening tests for microalbuminuria.The usual way to do this is to measure 
the albumin in a 24 hours sample of urine but the patient compliance is a 
limiting factor. An easier method is to measure the concentration of albumin 
in urine at patient initial visit especially the concentrated a morning sample. 
Several investigator have used this method reported comparable result  
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( Nathan DM, Rosenbaum C, Protasowicki D. Single-void urine samples can 
estimate quantitative microalbuminuria. Diabetes Care 1987;10:414-8. 
Schwab SJ, Dunn FL, Feinglos MN. Screening formicroalbuminurea. Diabetes 
Care 1992;15:1581-4.) 
 
Nonanalytical sources of variation 
Transient increases of urinary albumin excretion have been reported with 
short-term hyperglycemia, exercise, urinary tract infections, marked 
hypertension, heart failure and acute febrile illness  
 
Frequency of measurement 
The ADA recommends annual measurement for microalbumin in patients with 
negative (“dipstick”) results for overtproteinuria. After the documentation of 
a diagnosis of microalbuminuria (i.e., with results as defined above on 2 of 3 
tests performed within a period of 3 – 6 months), repeated testing is 
reasonable to determine whether a chosen therapy is effective. It may also 
be useful in determining the rate of progression of disease and thus support 
planning for careof end-stage renal disease. Although the ADA 
recommendations suggest that such testing is not generally needed 
before puberty, testing may be considered on an individual basis if it appears 
appropriate because of early onset of diabetes,poor control or family history 
of diabetic nephropathy. A recent study indicates that the duration of 
diabetesprior to puberty is an important risk factor in this age group and thus 
can be used to support such testing in individualpatients . 
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AIMS AND OBJECTIVES 
 
1. To study the prevalence of microalbuminuria in patients with 
newly detected  diabetes mellitus 
 
2. To study whether the occurrence of microalbuminuria has any 
correlation with the occurrence of diabetic retinopathy.  
 
3. To find out whether other factors like age, sex, obesity, smoking, 
alcohol, dietary  habits have any relationship with 
microalbuminuria. 
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MATERIALS AND METHODS 
 
SETTING 
All  Patients included in this study were those attending the 
Diabetology OP, GRH, Madurai. 
 
COLLABORATING DEPARTMENTS 
 Department of Medicine  
 Department of Diabetology 
 Department of Bio Chemistry 
 Department of Ophthalmology 
 
DESIGN OF STUDY 
 Cross sectional Observational study 
 
PERIOD OF STUDY 
 One year from September, 2004. 
 
SAMPLE SIZE 
61 patients went included in the study which included  21 males 
and                 40 females. 
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SELECTION OF STUDY SUBJECTS / MATERIALS 
 
Patients who satisfied the WHO criteria for diabetes ( newly  
diagnosed ) were included in the study. A full history, physical 
examination and the necessary investigations were done for all 
the patients. Patients age, sex, height and  weight were 
recorded and  BMI was calculated by using the formula  weight / 
height2.  Fasting and 2 Hours post prandial blood glucose Were 
obtained as per WHO norms Blood Pressure was recorded for the 
patients on at least two occasions   and patients whose BP was 
>140/90 were excluded from the study. An ocular fundus 
examination was done with the help of Ophthamology  
Department for all patients Urine was tested for Albuminuria and 
those who had clinically overt proteinuria were excluded from 
the study. Other patients who had fever infections chronic 
Kidney disease, were excluded from the study. 
One random sample of urine was obtained preferably early 
morning for quantifying albumin level in urine. This method is 
superior to the excretion rate and an accurate method for 
screening of micro albuminuria. 
 
 32
PROCEDURE OF TEST 
 
Micro albuminuria test was done using the TINA – QUANT 
Albumin test. The method adapted was the Immunoturbidimetric 
assay. Samples of urine  were collected using standard sampling 
tubes, centrifuged and then analyzed in ROCHE / HITACHI / 902 
modular analyzer. This method has been standardized against 
CRM 470. Measuring range of this analyzer was from  3 – 400 
mg/L. 
 
ETHICAL APPROVAL 
 Ethical committee clearance obtained. 
 
CONSENT 
 Informed consent from subjects obtained. 
 
STATISTICAL ANALYSIS 
Computer analysis of data done using the software 
epidemiological information package 2002 developed by Centre 
for Disease Control and Prevention, Atlanta  in collaboration with 
world Health Organization. Chisquare test was used   for tests of 
significance. 
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RESULTS AND ANALYSIS 
A. Characteristics of Study Population : 
 
1. SEX 
Characteristics No % 
Males 21 34.4 
Females 40 65.6 
Total 61 100 
 
2. AGE 
Characteristics No % 
< 30 5 8.2 
31-40 11 18.1 
41-50 19 31.1 
51-60 21 34.4 
> 60 5 8.2 
Total 61 100 
Mean 47.9 
S.D. 11.4 
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3.BMI 
 
Characteristics No % 
Lean ( <20) 4 6.6 
Normal ( 20=25) 23 37.7 
Obese  ( >25) 34 55.7 
Mean 24.95 
S.D. 3.77 
 
4. D.M.Type 
 
D.M.Type No % 
Type 1 2 3.3 
Type 2 58 95.1 
Type3 1 1.6 
 
5:Sex and MAU 
MAU values 
Normal Abnormal 
Sex 
No % No % 
Mean S.D. 
Males 15 71.4 6 28.6 21.1 14.5 
Females 29 72.5 11 27.5 17.6 10.8 
    ‘p’ value =   0.4298         ( Not Significant ) 
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6: BMI and MAU 
MAU values 
Normal Abnormal 
BMI 
No % No % 
Mean S.D. 
Lean 3 75 1 2.5 15.4 5.2 
Normal 16 67.6 7 30.4 19.3 13.5 
Obese 25 73.5 9 26.5 18.8 12.1 
    ‘p’ value =   0.5751         ( Not Significant ) 
7: Family history of diabetes and MAU 
MAU values 
Normal Abnormal 
Family history 
No % No % 
Mean S.D. 
Yes 10 100 - - 13.9 2.5 
No 34 66.7 17 33.3 19.7 13.1 
    ‘p’ value = 0.0275           (  Significant ) 
8: Smoking and MAU ( among males ) 
MAU values 
Normal Abnormal 
Smoking 
No % No % 
Mean S.D. 
Yes 3 100 - - 14.5 4.4 
No 12 66.7 6 33.3 22.2 15.4 
    ‘p’ value = 0.3923           ( Not Significant ) 
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9: Alcoholism and MAU 
MAU values 
Normal Abnormal 
Alcoholism 
No % No % 
Mean S.D. 
Yes 2 100 - - 16.0 4.9 
No 42 71.2 17 28.8 18.9 12.4 
    ‘p’ value =  0.8872          ( Not Significant ) 
 
10: Fasting B.S. and MAU 
MAU values 
Normal Abnormal 
Fasting B.S. 
No % No % 
Mean S.D. 
Normal 6 60 4 40 19.8 9.7 
Abnormal 38 74.5 13 25.5 18.6 12.7 
    ‘p’ value =    0.2751        ( Not Significant ) 
 
11: P.P.B.S. and MAU 
MAU values 
Normal Abnormal 
P.P.B.S. 
No % No % 
Mean S.D. 
Normal 4 100 - - 13.3 2.9 
Abnormal 40 70.2 17 29.8 19.1 12.6 
    ‘p’ value =   0.512         ( Not Significant ) 
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12: Cholesterol and MAU 
MAU values 
Normal Abnormal 
Cholesterol 
No % No % 
Mean S.D. 
Normal 16 76.2 5 23.8 18.4 13.8 
Abnormal 28 70 12 30 19 11.8 
    ‘p’ value =  0.7326          ( Not Significant ) 
 
13: Retinopathy and MAU 
MAU values 
Normal Abnormal 
Retinopathy 
No % No % 
Mean S.D. 
Yes 3 37.5 5 62.5 25.3 14.5 
No 40 75.5 13 24.5 17.8 11.7 
   ‘p’ value = 0.042           (  Significant ) 
14: D.M. Type and MAU 
MAU values 
Normal Abnormal 
D.M. Type 
No % No % 
Mean S.D. 
Type 1 2 100 - - 10.5 - 
Type 2 42 72.4 16 27.6 19 12.4 
Type 3 - - 1 100 22.8 - 
    ‘p’ value =    0.5169        ( Not Significant ) 
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RESULTS: 
 
This study was conducted in the Diabetology OP ,Government Rajaji 
Hospital, Madurai and included those diabetic patients who were newly 
diagnosed to be having diabetes mellitus, to estimate the prevalence 
of Microalbuminuria and its association with other variable like age, 
sex, family history ,fasting and postprandial blood sugar values, and in 
particular Diabetic Retinopathy. 
 
Total number of subjects included in this study was  61. Of this 
females predominated with  40 (65.6 % ) and males were only 21 
(34.4 % ). Only two cases ( 3.3 % ) were that of  Type 1 Diabetes , 
both of them being females and one case ( 1.6 % ) was that of 
Gestational Diabetes Mellitus , the rest being that of  Type 2 Diabetes. 
 
The overall prevalence of MAU among study population was 28%.  
Among males Microalbuminuria was present in 6 ( 28.6 % ) and 
absent in  15 ( 71.4 % ). Among females Microalbuminuria was 
Present in  11 (27.5 % ) and absent in 29 (72.5 % ). There was no 
significant correlation of Microalbuminuria with sex ( P = 0.4298, not 
significant  ). 
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Among the study subjects, the majority was that of the age group 51 
to 60 Years ( 21 i.e.34.4 % ),followed by 41 to 50 Years ( 19 i.e.31.1 
% ), 31 to 40 Years ( 11 i.e. 18.1 % ), 30 Years and below ( 5 i.e. 8.2 
% ), more than 60 Years ( 5 i.e.8.2 %  ). Of the 5 persons among 30 
Years and below, 2 were those of  Type 1 Diabetes  and 1 was that of 
Gestational Diabetes Mellitus, so the incidence of  Type 2 Diabetes  
was least in this group ( 2 persons only ). 
 
Among the study subjects, Body Mass Index was abnormal ( <20 & 
>25 ) in 38 ( 62.3 % ) of the study subjects, 4 ( 6.6 % ) were 
classified under lean ( Body Mass Index <20 ), mean was 15.4 and 
S.D. was 5.2.  23 persons ( 37.7 % ) had normal Body Mass Index  
( 20 to 25 ),the mean was 19.3 and S.D.13.5.  34 Persons ( 55.7 % ) 
were obese ( Body Mass Index > 25 ), the mean was 24.95 and S.D 
was 3.77. Among those with abnormal Body Mass Index ( 38 Persons ) 
Microalbuminuria was present in 10  and absent in 28. Among those 
with normal Body Mass Index , Microalbuminuria was present in 7 and 
absent in 16. There was no significant correlation of Microalbuminuria 
with Body Mass Index ( P = 0.5751 ). 
Family history was positive in only 10 persons ( 16.4 % ). All the 10 
persons who had positive family history did not have Microalbuminuria. 
Among the subjects who did not have family history ( 51 i.e. 83.6 % ) 
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17 persons had Microalbuminuria and 34 did not have it. Hence this 
factor  had a significant correlation with Microalbuminuria                   
( P = 0.0275, Which was significant ). The mean  and S.D. was 13.9 
and 2.5 respectively among those with  a positive family history and 
19.7 and 13.1 among those with a negative  family history. 
 
Smoking history was present in only 3 ( 14.3 % ) of the study 
population. All 3 smokers  were males. All 3 smokers did not have 
Microalbuminuria. Of the non-smokers ( 18 i.e. 85.7 %), 12 persons 
did not have Microalbuminuria and 6 had Microalbuminuria. Hence 
smoking was not significantly correlated with Microalbuminuria 
( P = 0.3923,  not significant ). The mean  and S.D. was 14.5 and 4.4 
respectively among those with  a positive smoking history and 22.2 
and 15.4 among those with a negative  smoking history. 
 
Alcoholism history was present in only 2 ( 3.3 % ) of the study 
subjects. Both of them were males. Of the non-alcoholics 17 ( 28.8% ) 
had Microalbuminuria and 42 ( 71.2 % )did not have it. The correlation 
between Microalbuminuria and alcoholism was not significant.             
( P = 0.8872,  not significant ). The mean  and S.D. was 16 and 4.9 
respectively among those with  a positive alcoholism history and 18.9 
and 12.4 among those with a negative alcoholism   history. 
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Since only normo-tensive subjects only included in this study the 
correlation  of Microalbuminuria with hypertension could not be arrived 
at. The mean systolic blood pressure was 126.8  ( S.D. 10.4 ) and 
mean diastolic blood pressure was 81.6 (S.D. 5.5 ) 
 
Fasting hyperglycemia was present in 51 persons ( 83.6 % ), out of 
which 13 persons had Microalbuminuria and 38 did not have it. The 
mean fasting blood glucose was 193.3 (S.D. 64.9 ). Fasting blood 
glucose was normal in 10 persons, out of which 4 (6.6 % )had 
Microalbuminuria and 6 did not have it. The correlation between 
Microalbuminuria and fasting blood glucose was not significant.           
( P = 0.2751, not significant ). 
 
Post prandial blood glucose levels were in the diabetic range in 57 
(93.4 % ) of the study subjects out of which 17 had Microalbuminuria 
and 40 did not have it. The mean Post prandial blood glucose was 
301.6 ( S.D.93.3 ) Only 4 persons had post prandial blood glucose 
levels in non-diabetic range. The correlation between Microalbuminuria 
and post prandial blood glucose was not significant. ( P = 0.042, not 
significant ). 
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There were only 2 patients of  Type 1 Diabetes . Both of them did not 
have Microalbuminuria and 1 cases of Gestational Diabetes Mellitus 
which had Microalbuminuria. Among the Type 2 Diabetes  ( 42 ) 
patients Microalbuminuria was present in 16 (27.6 % ) and absent in 
42 (72.4 % ). The correlation between Microalbuminuria and type of 
diabetes was not significant ( P = 0.5169, not significant ) This may 
due to the small size of samples.  
 
The prevalence of Diabetic retinopathy in our study population was   
13 %This study showed a high prevalence of Microalbuminuria among 
newly diagnosed diabetes  and a significant correlation of 
Microalbuminuria with diabetic retinopathy. 
 
Interpretation from the statistical analysis was mainly done to 
estimate the prevalence of Microalbuminuria among the study subjects 
and the correlation between Microalbuminuria and various other 
variables particularly diabetic retinopathy, so that early detection of 
Microalbuminuria and there by the complications would be possible.  
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DISCUSSION 
 
Microalbuminuria is a useful predictor of renal failure 
in patients with Diabetes mellitus and even an independent predictor 
of mortality in Type 2 Diabetes  as shown by studies don by ( Neil, 
Hawkins M, Potok-M  et al – Diabetes care 1993 ) 
 
Microalbuminuria is also associated with Diabetic 
Retinopathy in Type 2 Diabetes  and is a reliable maker for Diabetic 
Retinopathy – as shown by studies done by Dept. of Medicine, Furness 
General hospital, UK and Eric Mogensen, Arhus University hospital, 
Denmark. 
 
The Center for Disease Control and prevention   
(CDC ) recommends early detection of Microalbuminuria in patients 
with Diabetes Mellitus. – Atlanta, Department of health and human 
services 1991. 
 
In this study we have attempted to estimate the 
extent of this problem –i.e. the prevalence of Microalbuminuria among 
patients with newly detected Diabetes Mellitus, at the OP clinic, 
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Department of Diabetology, GRH, Madurai and its role as a marker for 
Diabetic Retinopathy. 
The prevalence of Microalbuminuria in patients 
Diabetes mellitus- both old and newly detected has been high and 
varying among different studies conducted in population of various 
races and Geographic area. This study showed the prevalence of 
Microalbuminuria to be 28% among all newly detected Diabetes 
Mellitus patients which is a very high prevalence olivarious at all found 
Microalbuminuria 33.6% among males and 28.8 % among females of 
newly diagnosed diabetes. The slight variation from our study could be 
due to the different  methods used. The prevalence was 21% in 
studies done by Vijay Viswanathan, Seena R, Lalthia S and 27.5 % in a 
study done by Varghese A, Deepa R, Rema  M  et al. 
 
In studies done by Winconsin study, Danish 
population study and Pima Indians, Age was significantly correlated 
with Microalbuminuria. But in a study conducted by Department of 
Medicine, Furness General Hospital, UK age was not significantly 
correlated with Microalbuminuria . In our study Microalbuminuria was 
not significantly correlated with age. The above studies had good 
correlation probably because they included all Diabetes patients old 
and new and due to racial variations. 
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Sex was not significantly correlated with 
Microalbuminuria in our study. In previous studies done by Johet  et 
al, males had a higher prevalence of Microalbuminuria but in studies 
done by Vijay et al, From Madras, Sex did not have a good correlation 
with Microalbuminuria. The observation that male sex significantly 
correlated with Microalbuminuria in Western study could be due to 
difference in races, and genetics of them when compared with us. 
 
Smoking and alcohol was not significantly correlated 
with Microalbuminuria in our study. Most of the studies conducted by 
western people have revealed a significant correlation of smoking and 
alcoholism with Microalbuminuria. This probably may be due to the 
fact that all smokers observed in this study were males and that 
females were predominant in this study in western community females 
form a high proportion of smoker which is not seen in our study 
population. This may probably explain the weak significance of 
smoking and alcoholism with Microalbuminuria in our study. 
 
In NHANES III study, and studies done by Niskanes, 
Sarlaud et al  BMI was significantly correlated with Microalbuminuria. 
BMI was not significantly correlated with Microalbuminuria in our 
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study. This may be due to the fact that Asians & Indians in particular 
are more susceptible to development of central (abdominal ) Adiposity 
even among healthier people. This has a greater influence on BMI 
when compared to western population who have less incidence of 
central adiposity & Obesity among healthier population. 
 
Family history was significantly correlation with 
Microalbuminuria in our study population This study actually showed 
an inverse correlation of Microalbuminuria with family history which 
was in contrast to many other studies conducted by Vijay et al from 
Madras which showed a direct correlation with family history. This 
variation may be due to referral bias, which might have resulted from 
patients awareness to reach of hospital when one of their  relatives 
had DM. Familial clustering  present in previous studies could be due 
to genetic susceptibility linked to Angiotensin encoding gene as shown 
in OJI-Kree Indians. 
 
Fasting blood sugar and post prandial was 
significantly correlated with Microalbuminuria in studies conducted by 
Vijay et al Madras and Panning H, Leuis JB, Rasid M et al. But in our 
study there was not any significant correlation of MAU with either 
fasting blood glucose or postprandial blood glucose.This may be due to 
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referral bias of GRH as a tertiary care center where patients are 
referred late when both FBG and PPBG are abnormal or racial 
differences among the study groups. 
 
Lipid profile was abnormal and significantly 
correlated with Microalbuminuria ( LDL & HDL ) in various studies 
conducted by Parrin H, Levis JB et al and Viajy et al,Madras. But in one 
study serum cholesterol did not significantly correlated with 
Microalbuminuria. This could be probably due to the fact that a 
complete lipid profile ( which was not done among our patients ) would 
have been obtained and the total serum cholesterol was not of much 
significance in relation to Microalbuminuria. 
 
The prevalence of diabetic retinopathy in our study 
population was high Microalbuminuria was significantly associated with 
diabetic retinopathy in studies conducted by Masored Mananiot, Mohd 
Agkhamine et al Iran, and by Arun, Ngugi, Lovelock et al,  Winconsin 
Epidemiology study of Diabetic Retinopathy. 
 
In our study also Microalbuminuria was significantly 
correlated with Diabetic retinopathy. This showed that 
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Microalbuminuria is a useful and reliable marker for early detection of 
diabetic retinopathy. 
 
It is clear in this study and other that 
Microalbuminuria and Diabetic Retinopathy is quiet prevalent among 
newly diagnosed Diabetes. It is also clearly evident that 
Microalbuminuria is significantly correlated with Diabetic Retinopathy 
among newly diagnosed Diabetes. 
 
This obviates the necessity for early detection and 
treatment. The  American Diabetes Association recommend annual 
testing for Microalbuminuria for persons who have had Diabetes for 
five Years of move.But in a population like that of ours which report 
to the health system only in advanced stages of disease or only when 
symptoms develop. There is a huge necessity for screening newly 
detected Diabetes for complication and marker for complications like 
Microalbuminuria even at the time of Diagnosis itself, for prevent 
further dangerous complication like nephropathy ,retinopathy and 
possible other vascular complication also. 
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CONCLUSION 
 
 
 
 
 
1. In this study of 61 patients with newly detected diabetes, there 
was a high prevalence of microalbuminuria . 
 
2. The presence of microalbuminuria   in newly detected diabetes 
was significantly correlated with diabetic retinopathy and 
negatively correlated with family history. 
 
3. This study also showed that other variables like age, sex, BMI, 
FBG, PPBG, smoking, alcoholism and serum cholesterol 
did not correlate significantly with microalbuminuria in newly 
detected diabetes. 
 
4. Therefore urinary screening for microalbumuria in newly  
detected diabetes, improves the early detection and   primary 
prevention of diabetic complications. 
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SUMMARY 
 
 
 
 This study shows a high  prevalence of MAU ( 28%) among 
newly diagnosed Diabetic population which was in concurrence with 
the earlier studies conducted by Olivarius et al , Vijay Viswanathan , 
Seena R, et al and Varghese A, Deepa R, et al. 
 
The prevalence of Diabetic Retinopathy in our study population was 
very High ( 13 %  ). This study also showed a statistically  significant 
correlation of MAU with Diabetic retinopathy ( which was present in  
5 persons with MAU and 3 without MAU ).This was also the observation 
of  Vinconsin, Epidemiologic study on retinopathy and studies 
conducted by Mohamed Afkhami, Manaviat, et al, Iran. 
 
 This study shows a significant negative correlation of MAU with 
family history of Diabetes ( P = 0.0275 ). 10 ( 100 % ) of family 
history positive Diabetes did not have MAU, where as 17 persons 
among those who did not have family history had MAU. This 
observation was in contrast to many of the previous  observations of 
Vijay et al, Chennai. 
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This study also showed that other variables like age, sex, BMI, 
FBG,PPBG, smoking, alcoholism and serum cholesterol 
did not correlate significantly with microalbuminuria in newly 
detected diabetes. 
 
Therefore urinary screening for microalbumuria in newly 
detected diabetes, improves the early detection and   primary 
prevention of diabetic complications. 
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PROFORMA 
 
MICROALBUMINURIA IN  NEWLY DETECTED  DIABETES MELLITUS  AS 
A RISK FACTOR FOR DIABETICS RETINOPATHY 
 
 
 
NAME:      OCCUPATION:   
        
AGE:       ADDRESS: 
 
SEX:       OP NO.: 
 
 
PRESENTING SYMPTOMS AT THE TIME OF DETECTION: 
 
POLY URIA   (   )   ITCHING   (   ) 
 
NOCTURIA   (   )   VOMITING   (   ) 
 
POLYDYPSIA   (   )   ABDOMINAL PAIN  (   )  
 
TIREDNESS   (   )   CONSTIPATION  (   ) 
 
WEIGHT LOSS  (   )   PRURTITUS VULVAE (   ) 
 
GIDDINESS   (   )   SEXUAL DYSFUNCTION (   ) 
 
BLURRING OF VISION (   )   NOCTURNAL DIARRHOEA (   ) 
 
SKIN INFECTION  (   )   BALANITIS   (   ) 
 
ULCER   (   ) 
 
 
PAST ILLNESS: 
 
MYOCARDIAL INFARCTION (   )   AMOEBIASIS (   ) 
 
HYPERTENSION   (   )   MUMPS  (   ) 
 
PULMONARY TUBERCULOSIS (    )   ACCIDENTS  (   ) 
 
JAUNDICE    (   )   OPERATIONS (   ) 
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FAMILY HISTORY OF DIABETES: 
 
FATHER   (   )   BROTHERS   (   ) 
 
MOTHER   (   )   SISTERS   (   ) 
 
SONS    (   )   WIFE    (   ) 
 
DAUGHTERS   (   )   HUSBAND   (   ) 
 
HEAVY BABIES  (   ) 
 
 
PERSONAL HISTORY: 
 
SMOKING   (   )   ALCOHOL   (   ) 
 
VEGETARIAN  (   )   NON-VEGETARIAN  (   ) 
 
SEDENTARY    (   )   ACTIVE:   (   ) 
 
 
PHYSICAL EXAMINATION: 
 
HEIGHT:    WEIGHT :    BMI: 
     
 
BLOOD PRESSURE:   OBESE / NON-OBESE: 
 
XANTHOMA:    XANTHELASMA: 
 
THYROID SWELLING: 
 
 
FUNDUS EXAMINATION: 
 
NO RETINOPATHY         (   ) 
 
NONPROLIFERATIVE DIABETIC RETINOPATHY    (   ) 
 
    MILD       (   ) 
 
    MODERATE      (   ) 
     
    SEVERE      (   ) 
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PROLIFERATIVE DIABETIC RETINOPATHY     (   ) 
 
 
SYSTEMIC EXAMINATION: 
 
CVS:       RS: 
 
ABDOMEN:      CNS: 
 
 
VASCULAR COMPLICATIONS: 
 
IHD:      YES / NO 
 
PVD:      YES / NO 
 
CARDIOMYOPATHY:   YES / NO 
 
RETINOPATHY:    YES / NO 
 
NEPHROPATHY:    YES / NO 
 
NEUROPATHY:    YES / NO 
  
 
INVESTIGATIONS: 
 
BLOOD GLUCOSE:       URINE: 
 
 FASTING   :     ALBUMIN: 
 
 2 HOURS POSTPRANDIAL:         SUGAR: 
 
BLOOD UREA:           DEPOSITS: 
 
SERUM CREATININE: 
                   
SERUM CHOLESTEROL: 
      
ECG: 
 
 
MICROALBUMINURIA: 
 
TYPE OF DIABETES: 
  
TYPE 1   (   )    TYPE 2  (   ) 
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MASTER CHART 
 
S.No AGE SEX BMI FAM.HIS SMOKE ALCOHO SYS.BP DIA.BP FSG PPBS CHOL MAU RETINO DM TYPE 
1 46 M 26 N N N 130 80 130 213 216 12.3 No 2 
2 74 M 24.9 N N N 130 84 95 265 280 37.2 yes 2 
3 42 F 22 N N N 130 90 155 255 230 32.2 No 2 
4 34 F 24.9 N N N 120 76 315 332 210 15 No 2 
5 55 F 26 N N N 130 80 212 271 202 11 No 2 
6 38 F 27.1 N N N 130 82 187 338 260 21 No 2 
7 37 F 32.4 N N N 130 82 140 226 169 29.7 No 2 
8 51 F 28 N N N 132 84 101 142 171 17.3 No 2 
9 45 F 24 N N N 114 80 110 280 184 12 No 2 
10 34 F 23.8 N N N 110 80 244 351 284 11.5 No 2 
11 45 F 26.2 N N N 130 76 170 270 212 14.3 No 2 
12 50 F 25.6 N N N 146 84 279 480 214 11.9 No 2 
13 70 F 27.9 N N N 120 90 153 247 210 62.1 yes 2 
14 60 F 21.6 Y N N 140 80 124 240 178 10.2 No 2 
15 36 F 22.2 N N N 130 80 244 414 227 26.7 No 2 
16 45 M 14.7 Y N N 122 80 190 260 150 13.1 No 2 
17 60 F 19.1 N N N 120 80 124 202 208 23.2 yes 2 
18 55 F 26.8 Y N N 130 80 280 360 162 12.6 No 2 
19 46 M 26 N N N 130 80 130 213 216 12.3 No 2 
20 45 F 27 N N N 140 88 120 160 220 12.6 No 2 
21 48 F 20.3 N N N 122 70 280 320 228 11 No 2 
22 60 F 26.3 N N N 128 74 128 220 240 12.6 No 2 
23 55 M 37.6 N N N 140 84 243 280 164 13 No 2 
24 52 F 27.8 N N N 140 86 200 280 246 31.4 No 2 
25 42 F 26 N N N 120 80 248 264 273 49.1 No 2 
26 46 F 18.6 N N N 100 70 204 248 200 13.2 No 2 
27 50 M 28.1 N N N 110 70 240 256 264 10.4 No 2 
28 45 M 24.2 N N N 136 82 132 180 190 13.1 No 2 
29 27 F 20 N N N 110 80 336 480 120 10.5 No 1 
30 39 M 25.8 N N N 120 90 164 264 146 48.1 yes 2 
S.No AGE SEX BMI FAM.HIS SMOKE ALCOHO SYS.BP DIA.BP FSG PPBS CHOL MAU RETINO DM TYPE 
31 54 F 28.5 N N N 130 88 220 252 145 10.9 yes 2 
32 27 F 20 N N N 110 80 336 480 120 10.5 No 1 
33 40 F 26.5 N N N 100 70 234 280 181 22 No 2 
34 68 M 22 N N N 130 70 142 296 140 61.9 No 2 
35 32 M 27.2 N N N 120 90 253 360 198 17.1 yes 2 
36 52 M 20 N N N 140 86 101 232 273 35.4 No 2 
37 47 M 27 Y N N 140 88 193 347 142 14.3 No 2 
38 44 F 27.4 Y N N 122 80 132 284 140 14 No 2 
39 39 F 27 N N N 126 70 145 198 208 10.3 No 2 
40 59 F 26.2 N N N 120 80 196 260 160 20.6 No 2 
41 52 F 22 Y N N 130 80 225 256 227 14.8 No 2 
42 55 M 29.1 N N N 130 86 238 421 287 13 No 2 
43 60 M 24.2 Y N N 130 80 115 313 229 13.2 No 2 
44 45 M 27 Y Y Y 120 78 148 297 250 19.5 No 2 
45 51 M 22 Y Y N 122 80 252 496 260 11.4 No 2 
46 55 M 26 N N N 130 80 193 297 382 12.5 No 2 
47 35 F 27.5 N N N 130 86 151 219 218 12.6 No 2 
48 58 F 26 N N N 130 90 201 301 280 14 No 2 
49 48 M 25 N N N 140 88 148 229 302 40 yes 2 
50 60 F 27 N N N 122 80 247 466 313 10.2 No 2 
51 28 M 21.5 N N N 122 82 145 284 175 10 No 2 
52 68 F 31 N N N 132 88 126 210 210 15 No 2 
53 43 M 26 N N N 120 80 96 204 312 21.8 No 2 
54 60 F 20 N N N 140 88 272 499 213 10.5 yes 2 
55 51 M 22.6 N Y Y 120 88 289 544 187 12.5 No 2 
56 35 F 23.8 N N N 120 80 224 379 215 10.7 No 2 
57 43 F 20.5 N N N 140 82 130 210 234 10.3 No 2 
58 25 F 25 N N N 140 90 191 267 249 22.8 No 3 
59 60 F 26.3 N N N 146 80 254 416 320 14.6 No 2 
60 67 F 17.5 N N N 132 84 210 433 250 12.1 No 2 
61 30 F 29.3 Y N N 110 84 307 355 272 15.5 yes 2 
M = Male      F = Female        Y = Yes           N = No 
